Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Beta2 -adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular PKA signaling at therapeutic inhaled doses

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Changes in blood parameters after intramuscular testosterone ester injections - Implications for anti-doping

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. New insights for identification of doping with recombinant human erythropoietin micro-doses after high hydration

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Morten Hostrup
  • Christian K Narkowicz
  • Sajad Habib
  • David S Nichols
  • Glenn A Jacobson
View graph of relations

While studies have demonstrated substantial differences in beta2 -adrenergic agonist enantiomer pharmacology, enantioselective disposition of long-acting beta2 -adrenergic ligand racemic (rac)-formoterol in blood is inadequately explored after inhaled therapy given analytical challenges. Furthermore, information on enantioselective disposition and partitioning of beta2 -adrenergic agonist in skeletal muscle is absent despite its promising data on muscle anabolism in humans. Using a sensitive ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS/MS) assay, we determined disposition of (R,R)-formoterol and (S,S)-formoterol in plasma and skeletal muscle samples from 11 non-asthmatic men who had inhaled rac-formoterol at therapeutic doses (2 × 27 μg). Mean (SD) concentrations of (R,R)- and (S,S)-formoterol in plasma and in muscle biopsies of the vastus lateralis 1 hour after inhalation of formoterol were 31 (15) and 45 (18) pg × mL-1 for (R,R)-formoterol and (S,S)-formoterol, respectively, in plasma, and 0.56 (0.32) and 0.51 (0.29) pg × mgwet wt-1 , respectively, in muscle. Formoterol exhibited different enantioselective disposition in plasma and muscle (p < 0.0001). In plasma, mean log (R,R):(S,S)-formoterol ratio was lower than 0 [-0.17(0.07), p < 0.0001], whereas in muscle, mean log (R,R):(S,S)-formoterol ratio was slightly higher than 0 [0.04(0.07), p < 0.05]. Log (R,R):(S,S)-formoterol ratio in muscle was related to muscle fiber-type composition. Furthermore, formoterol induced an approximately two-fold increase in muscle p-PKASer/thr phosphorylation (p < 0.01), indicating a substantial beta2 -adrenergic response. Collectively, these findings suggest that formoterol exhibits modest enantioselective disposition in plasma after inhaled therapy in humans, which appear related to a greater (R,R)-enantiomer disposition in skeletal muscle that may be dependent on fiber-type composition.

Original languageEnglish
JournalDrug Testing and Analysis
Issue number7
Pages (from-to)1048-1056
Number of pages9
Publication statusPublished - Jul 2019

    Research areas

  • arformoterol, beta-2, beta-adrenoceptor, beta2-adrenoceptor, LABA

ID: 57232545